Cibisatamab
(Anti-human CEACAM5 mAb, human IgG1-Kappa; RG-7802)
Catalog No.: PC-Ab1057Not For Human Use, Lab Use Only.
Cibisatamab (CEA-TCB, RO-6958688) is a novel bispecific antibody immunotherapy that effectively brings the cancer cells and cancer-killing T cells of the immune system together, triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. It is efficacious in poorly infiltrated tumors where it increases T-cell infiltration and generates a highly inflamed tumor microenvironment..
Cibisatamab (CEA-TCB, RO-6958688) is a novel bispecific antibody immunotherapy that effectively brings the cancer cells and cancer-killing T cells of the immune system together, triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. It is efficacious in poorly infiltrated tumors where it increases T-cell infiltration and generates a highly inflamed tumor microenvironment.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
